NCT06812637View on ClinicalTrials.gov

Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 6, 2024

Primary Completion Date

June 6, 2024

Study Completion Date

September 2, 2024

Conditions
Diabetic Foot Ulcer (DFU)Exosomes
Interventions
DRUG

WJ-MSC- Exosomes

warton jelly derived mesenschymal stem cell derived exosomes dissolved in CMC

COMBINATION_PRODUCT

SOC (Standard of care)

Wound depridement for necrotic parts , local antibiotic , dressing , unloading

OTHER

Vehicle (placebo)

Vehicle for the MSC-EXO

Trial Locations (1)

33511

kafr elshaikh university Hospital, Kafrelsheikh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER

NCT06812637 - Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial | Biotech Hunter | Biotech Hunter